News Updates
More Articles
- Benefits of Integrating Patient Engagement with Diversity, Equity, and Inclusion in New Medical Product Development: A Call for Action
- Drug Shortages in the Global South: A Proposed Parallel Tech and Reg Transfer Framework
- Industry’s Window to Express Interest in Africa Continental Product Evaluation Pilot Closes End of February 2024
- Fair Pay for Patient Engagement: Navigating the Evolving Landscape of Remuneration
- The Importance of Regulatory Due Diligence During the Acquisition Process
Regulatory Utilization of Real-World Data and Real-World Evidence in Japan: Pharmaceuticals and Medical Devices Agency (PMDA) Chief Executive Perspective
In cases when a randomized controlled trial cannot be conducted because of the limited patient population for rare diseases or other reasons, the PMDA has been making good use of RWD/RWE for regulatory decision-making.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!